MINT-BUSPIRONE 10 MG
BUSPIRONE HYDROCHLORIDE : 10 MG · DIN 02519054 · MINT PHARMACEUTICALS INC
Health Canada status: MARKETED
What is MINT-BUSPIRONE?
MINT-BUSPIRONE 10 MG contains BUSPIRONE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02519054, held by MINT PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 26-Jan-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MINT-BUSPIRONE used for?
Short term symptomatic relief of excessive anxiety in patients with Generalized Anxiety Disorder (GAD). Effectiveness beyond 4 weeks not evaluated.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02519054 |
|---|---|
| Brand name | MINT-BUSPIRONE |
| Generic / active ingredient | BUSPIRONE HYDROCHLORIDE : 10 MG |
| Manufacturer | MINT PHARMACEUTICALS INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05BE01 BUSPIRONE |
| AHFS class | 28:24.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Jan-2022 |
| Original market date | 2022-01-26 00:00:00 |
How is it administered?
Initial: 5 mg 2-3 times daily. Titrate by 5 mg every 2-3 days. Usual dose: 20-30 mg daily in divided doses. Max: 45 mg daily. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard pharmaceutical storage typically applies, but text refers to Section 11 which is not fully provided).
How is it supplied?
HDPE Bottle packs of 100 and 500 tablets.
Contraindications
Hypersensitivity to buspirone; severe hepatic or severe renal impairment; use of MAO inhibitors within the last 14 days.
Warnings and precautions
Risk of addiction, abuse, misuse; withdrawal reactions; profound sedation/respiratory depression with opioids; serotonin syndrome; potential for falls/fractures.
Is BUSPIRONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05BE01 BUSPIRONE. 7 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMB-BUSPIRONE | 10 MG | TABLET | AMBICARE PHARMACEUTICALS INC. | MARKETED | DIN 02550555 |
| AURO-BUSPIRONE | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02500213 |
| JAMP BUSPIRONE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02509911 |
| PMS-BUSPIRONE | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02230942 |
| PRO-BUSPIRONE | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02223163 |
| TEVA-BUSPIRONE | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02231492 |
| APO-BUSPIRONE | 10 MG | TABLET | APOTEX INC | DORMANT | DIN 02211076 |
| BUSPAR TAB 10MG | 10 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 00603821 |
| BUSPIRONE | 10 MG | TABLET | APOTEX INC | APPROVED | DIN 02207672 |
| BUSPIRONE | 10 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02447851 |
Who else supplies BUSPIRONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUSPIRONE appears in 15 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.